This randomised , open label , phase I , immunotherapeutic study investigated the effects of interleukin ( IL ) -2 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , recombinant human growth hormone ( rhGH ) , and therapeutic immunisation ( a Clade B DNA vaccine ) on combination antiretroviral therapy ( cART ) - treated HIV-1-infected individuals , with the objective to reverse residual T-cell dysfunction .